Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319901 · ClinicalTrials.gov registry record · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
A Phase 1 study of Leukemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 5
- Study locations
NCT03319901 is a Phase 1 study of Leukemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 82 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03319901, a Phase 1 study of Leukemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Standard Chemotherapy
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Illinois
- University of Chicago - Chicago
Texas
- MD Anderson Cancer Center - Houston
Utah
- Intermountain LDS Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03319901
The ClinicalTrials.gov registry entry for NCT03319901 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (83% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT03319901 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT03319901 about?
NCT03319901 is a clinical study titled "Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL". This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, ...
What is the current status of trial NCT03319901?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2017-10-30. Estimated completion is 2027-04-30.
What conditions does trial NCT03319901 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT03319901?
The interventions under investigation include: Venetoclax (DRUG), Standard Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03319901?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03319901 being conducted?
This trial has 5 study locations across Illinois, Massachusetts, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.